Austedo vs. Ingrezza: Understanding Your Options for Movement Disorders

Living with involuntary movements can significantly impact daily life, affecting everything from basic tasks to social interactions. For individuals experiencing conditions like tardive dyskinesia (TD) or chorea associated with Huntington's disease (HD), finding effective treatment is paramount. Two prominent medications that have revolutionized the management of these challenging movement disorders are Austedo (deutetrabenazine) and Ingrezza (valbenazine). Both belong to a class of drugs known as vesicular monoamine transporter 2 (VMAT2) inhibitors, but they possess distinct characteristics, indications, and considerations.

This comprehensive guide aims to provide an in-depth comparison of Austedo and Ingrezza, exploring their mechanisms of action, approved uses, dosage, potential side effects, and other crucial factors. By understanding the nuances of each medication, patients, caregivers, and healthcare providers can make informed decisions tailored to individual needs and circumstances. We will also delve into the conditions these drugs treat, offering insights into their symptoms, causes, and diagnostic approaches, alongside important information on when to seek medical advice and potential prevention strategies.

Understanding Movement Disorders: Tardive Dyskinesia and Huntington's Disease

Before diving into the specifics of Austedo and Ingrezza, it's essential to understand the conditions they are designed to treat. Both tardive dyskinesia and Huntington's disease involve involuntary movements, but their underlying causes and broader clinical pictures differ significantly.

Tardive Dyskinesia (TD)

Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive body movements. The term "tardive" means "late-appearing," referring to the delayed onset of symptoms after prolonged exposure to certain medications.

Symptoms of Tardive Dyskinesia

• Facial Movements: Often the most noticeable, these can include grimacing, blinking, lip smacking, puckering, chewing, or tongue protrusion.
• Oral Movements: Involuntary movements of the tongue, jaw, and mouth are common, sometimes interfering with speech, eating, or swallowing.
• Limb Movements: Rapid, jerky, or writhing movements of the arms, hands, legs, and feet. Fingers may tap or drum involuntarily.
• Trunk Movements: Less common but can involve rocking, twisting, or thrusting movements of the torso.
• Respiratory Irregularities: In rare severe cases, diaphragm movements can be affected, leading to irregular breathing.

These movements are typically uncontrollable and can range from mild to severe, significantly impacting a person's quality of life, self-esteem, and social interactions. They can be distressing and often worsen with stress or anxiety, sometimes disappearing during sleep.

Causes of Tardive Dyskinesia

The primary cause of TD is long-term use of dopamine receptor blocking agents (DRBAs). These medications are most commonly:

• Antipsychotic Medications: Especially older, first-generation (typical) antipsychotics like haloperidol, chlorpromazine, and fluphenazine, used to treat schizophrenia, bipolar disorder, and other psychiatric conditions. Second-generation (atypical) antipsychotics like olanzapine, risperidone, and quetiapine also carry a risk, though generally lower.
• Anti-emetic Medications: Drugs used to treat nausea and vomiting, such as metoclopramide (Reglan), can also induce TD with prolonged use.

The exact mechanism is thought to involve dopamine receptor hypersensitivity in certain brain regions, developing as an adaptation to chronic dopamine blockade. When the blocking agent is reduced or stopped, these hypersensitive receptors overreact to available dopamine, leading to uncontrolled movements.

Diagnosis of Tardive Dyskinesia

Diagnosing TD is primarily clinical, based on observing characteristic involuntary movements in a patient with a history of exposure to dopamine receptor blocking medications. Key diagnostic steps include:

• Clinical Observation: A neurologist or psychiatrist will observe the patient for typical movements.
• Medical History: A thorough review of the patient's medication history is crucial, particularly for antipsychotics or anti-emetics.
• Abnormal Involuntary Movement Scale (AIMS): This standardized rating scale is widely used to quantify the severity of involuntary movements and track changes over time. It assesses movements in facial/oral, extremity, and truncal regions.
• Differential Diagnosis: It's important to rule out other conditions that can cause similar movements, such as other forms of dyskinesia, tics, tremors, or chorea from other causes.

Early diagnosis is important as symptoms can become more persistent and severe if left untreated.

Huntington's Disease (HD)

Huntington's disease is a progressive, inherited neurodegenerative disorder that causes the uncontrolled breakdown of nerve cells in the brain. This deterioration leads to a wide range of motor, cognitive, and psychiatric symptoms.

Symptoms of Huntington's Disease

HD symptoms typically appear between ages 30 and 50, but onset can vary widely. Symptoms progressively worsen over 10 to 25 years. They are broadly categorized:

• Motor Symptoms:
  • Chorea: The hallmark symptom, characterized by involuntary, jerky, dance-like movements of the face, trunk, and limbs. This is the primary motor symptom Austedo targets.
  • Dystonia (sustained muscle contractions leading to twisting or repetitive movements and abnormal postures).
  • Impaired gait, posture, and balance.
  • Difficulty with speech (dysarthria) and swallowing (dysphagia).
  • Slowed or rigid movements (bradykinesia/rigidity) in later stages.
• Cognitive Symptoms:
  • Difficulty with planning, organizing, problem-solving, and prioritizing (executive dysfunction).
  • Lack of flexibility in thought.
  • Difficulty learning new information.
  • Slowed thought processing.
  • Impaired memory.
• Psychiatric Symptoms:
  • Depression, irritability, and anxiety are common.
  • Obsessive-compulsive disorder (OCD) symptoms.
  • Mania or bipolar disorder.
  • Psychosis (delusions and hallucinations) in some cases.
  • Suicidal ideation and attempts are a significant concern.

The combination of these symptoms profoundly affects a person's ability to work, maintain relationships, and perform daily activities, eventually leading to complete dependence.

Causes of Huntington's Disease

Huntington's disease is caused by a genetic defect on chromosome 4. Specifically, it involves an abnormal expansion of a CAG trinucleotide repeat in the HTT gene, which codes for the huntingtin protein. The normal gene has 10-35 CAG repeats, while individuals with HD typically have 36 or more repeats. The higher the number of repeats, the earlier the onset and often the more severe the symptoms.

HD is an autosomal dominant disorder, meaning a person only needs to inherit one copy of the defective gene from either parent to develop the disease. Each child of an affected parent has a 50% chance of inheriting the gene.

Diagnosis of Huntington's Disease

Diagnosis typically involves:

• Neurological Examination: Assessment of motor function (chorea, dystonia, gait), eye movements, reflexes, strength, and balance.
• Psychiatric Evaluation: To identify cognitive and behavioral changes.
• Family History: A detailed family history of HD is a strong indicator.
• Genetic Testing: A definitive diagnosis is made by a blood test that detects the abnormal CAG repeat expansion in the HTT gene. This test can confirm HD in symptomatic individuals and can also be used for presymptomatic testing in at-risk individuals, though this is a complex decision with significant ethical and psychological implications.
• Brain Imaging (MRI or CT scan): While not diagnostic for HD, these scans can show brain atrophy, particularly in the caudate and putamen, which are affected in HD. They also help rule out other conditions.

Genetic counseling is an integral part of the diagnostic process, especially for families with a history of HD.

Introducing the Medications: Austedo and Ingrezza

Austedo and Ingrezza represent significant advancements in the symptomatic treatment of movement disorders. Both are VMAT2 inhibitors, but their specific indications, dosages, and side effect profiles warrant a closer look.

Austedo (deutetrabenazine)

Austedo is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington's disease in adults.

Mechanism of Action

Austedo is a VMAT2 (vesicular monoamine transporter 2) inhibitor. VMAT2 is a protein responsible for packaging neurotransmitters like dopamine, norepinephrine, and serotonin into vesicles within nerve cells for release. By inhibiting VMAT2, Austedo reduces the amount of dopamine released into the synaptic cleft, thereby decreasing dopaminergic activity. In conditions like TD and HD chorea, excessive or dysregulated dopamine signaling is thought to contribute to the involuntary movements. Austedo works by normalizing this activity, leading to a reduction in chorea and dyskinesia.

Deutetrabenazine is a deuterated form of tetrabenazine. Deuteration involves replacing hydrogen atoms with deuterium (a heavier isotope of hydrogen) at specific positions on the molecule. This modification slows down the metabolism of the drug, leading to a longer half-life and more stable drug levels in the body compared to non-deuterated tetrabenazine. This allows for less frequent dosing and potentially a more favorable side effect profile.

Approved Uses

• Tardive Dyskinesia (TD): Austedo is approved for the treatment of involuntary movements in adults with TD.
• Chorea Associated with Huntington's Disease (HD): It is also approved for the treatment of the involuntary, jerky movements (chorea) that are a hallmark symptom of HD.

Dosage and Administration

Austedo is taken orally, typically twice daily. The dosage is individualized and titrated slowly over several weeks to achieve the optimal therapeutic effect while minimizing side effects. The starting dose is usually low, and it is gradually increased based on patient response and tolerability. It can be taken with or without food.

Side Effects

Like all medications, Austedo can cause side effects. Common side effects include:

• Somnolence (drowsiness)
• Diarrhea
• Dry mouth
• Fatigue
• Insomnia
• Nausea
• Anxiety

More serious side effects can occur, and it's crucial to be aware of them. Austedo carries a Boxed Warning regarding the risk of depression and suicidality in patients with Huntington's disease. Patients with HD are already at an increased risk of these psychiatric issues, and treatment with VMAT2 inhibitors can exacerbate them. Close monitoring for mood changes, agitation, and suicidal thoughts is essential, especially during dose adjustments.

Other serious side effects can include:

• Neuroleptic Malignant Syndrome (NMS): A rare but life-threatening reaction characterized by high fever, muscle rigidity, altered mental status, and autonomic dysfunction.
• QT prolongation: A heart rhythm abnormality that can increase the risk of serious arrhythmias.
• Parkinsonism: Worsening or development of Parkinson-like symptoms such as tremor, rigidity, and slowed movement.
• Akathisia: A feeling of inner restlessness and an urge to move.

Warnings and Precautions

Austedo should not be used in patients with Huntington's disease who are suicidal or have untreated depression. It is also contraindicated in patients with hepatic impairment, as it can lead to increased drug levels. Caution is advised in patients with a history of heart rhythm problems or those taking other medications that prolong the QT interval.

Ingrezza (valbenazine)

Ingrezza is a prescription medication approved by the FDA for the treatment of tardive dyskinesia in adults.

Mechanism of Action

Ingrezza is also a VMAT2 inhibitor, similar to Austedo. It selectively inhibits VMAT2, reducing the amount of dopamine released in the brain. This targeted reduction in dopamine transmission helps to normalize motor control pathways, thereby alleviating the involuntary movements associated with tardive dyskinesia. Valbenazine is a prodrug, meaning it is converted into its active metabolite, α-dihydrotetrabenazine (α-HTBZ), after administration. This active metabolite is responsible for the VMAT2 inhibition.

Approved Uses

• Tardive Dyskinesia (TD): Ingrezza is specifically approved for the treatment of tardive dyskinesia in adults. Unlike Austedo, it is not approved for chorea associated with Huntington's disease.

Dosage and Administration

Ingrezza is administered orally, once daily. This once-daily dosing regimen can be a significant advantage for patient adherence. The starting dose is typically 40 mg once daily, which may be increased to 80 mg once daily after one week, depending on patient response and tolerability. It can be taken with or without food.

Side Effects

Common side effects associated with Ingrezza include:

• Somnolence (drowsiness)
• Anticholinergic effects (e.g., dry mouth, constipation, blurred vision)
• Akathisia (restlessness)
• Headache
• Nausea
• Insomnia

Serious side effects, though less common, can include:

• QT prolongation: Similar to Austedo, Ingrezza can prolong the QT interval, increasing the risk of serious heart rhythm abnormalities.
• Parkinsonism: Worsening or development of Parkinson-like symptoms.
• Neuroleptic Malignant Syndrome (NMS): A rare but severe reaction.

Ingrezza does not carry the same Boxed Warning for depression and suicidality as Austedo, likely because it is not indicated for Huntington's disease, a condition with an inherent high risk of these psychiatric issues.

Warnings and Precautions

Ingrezza should be used with caution in patients with congenital long QT syndrome, a history of arrhythmias, or those taking other medications known to prolong the QT interval. Dose adjustments may be necessary for patients with hepatic impairment or severe renal impairment.

Austedo vs. Ingrezza: A Detailed Comparison

While both Austedo and Ingrezza are VMAT2 inhibitors used to treat tardive dyskinesia, several key differences inform treatment decisions.

Key Indications

This is arguably the most significant distinction:

• Austedo: Approved for both tardive dyskinesia and chorea associated with Huntington's disease.
• Ingrezza: Approved solely for tardive dyskinesia.

Therefore, for patients with Huntington's disease experiencing chorea, Austedo is the only FDA-approved VMAT2 inhibitor option among these two.

Mechanism and Pharmacokinetics

Both drugs inhibit VMAT2, but their chemical structure and metabolism differ slightly:

• Austedo (deutetrabenazine): Is a deuterated form of tetrabenazine. The deuteration slows its metabolism, resulting in a longer half-life and more stable drug levels, which contributes to its twice-daily dosing.
• Ingrezza (valbenazine): Is a prodrug that is metabolized to its active form, α-dihydrotetrabenazine (α-HTBZ). Its pharmacokinetic profile supports once-daily dosing.

These differences in metabolism and half-life contribute to their distinct dosing schedules and potentially subtle variations in their side effect profiles and drug interaction potential.

Efficacy in Clinical Trials

Both medications have demonstrated significant efficacy in reducing the severity of tardive dyskinesia in their respective clinical trials.

• Austedo: In studies like the ARM-TD and AIM-TD trials, Austedo significantly reduced AIMS scores (a measure of TD severity) compared to placebo. It also showed sustained efficacy over longer periods. For Huntington's chorea, the First-HD study demonstrated significant reduction in chorea severity.
• Ingrezza: The KINECT 2 and KINECT 3 trials showed that Ingrezza produced statistically significant improvements in AIMS scores compared to placebo in patients with moderate to severe TD.

Direct head-to-head comparative trials between Austedo and Ingrezza are limited. However, both drugs have shown robust efficacy as demonstrated in their respective placebo-controlled studies, leading to their FDA approvals. The choice between them for TD often comes down to other factors like side effect profile, dosing frequency, and patient-specific considerations.

Dosage Regimens

• Austedo: Typically dosed twice daily, requiring patients to remember two doses per day.
• Ingrezza: Offers the convenience of once-daily dosing, which can improve medication adherence for some patients.

The dosing frequency can be a significant factor in patient preference and adherence, especially for individuals who may have cognitive impairments or complex medication schedules.

Side Effect Profiles Compared

While both share some common side effects like somnolence and QT prolongation, there are notable differences:

• Depression and Suicidality: Austedo carries a Boxed Warning for increased risk of depression and suicidal ideation in patients with Huntington's disease. This is a critical consideration for HD patients and requires vigilant monitoring. Ingrezza does not have this specific warning.
• Akathisia: Both can cause akathisia, but some studies suggest a potentially lower incidence with Ingrezza.
• Anticholinergic Effects: Ingrezza can cause anticholinergic effects (e.g., dry mouth, constipation) due to its metabolic pathway, which are less prominent with Austedo.
• Parkinsonism: Both can cause or worsen Parkinson-like symptoms due to their dopamine-depleting effects. Careful titration is needed to balance dyskinesia reduction with potential Parkinsonism.

The overall tolerability profile can vary between individuals, making patient-specific assessment crucial.

Drug Interactions

Both medications are metabolized by the cytochrome P450 enzyme system, making them susceptible to drug interactions.

• Austedo: Is primarily metabolized by CYP2D6 and CYP3A4. Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine) can significantly increase Austedo exposure, requiring dose adjustments. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) also increase exposure but to a lesser extent. Concurrent use with reserpine or monoamine oxidase inhibitors (MAOIs) is contraindicated.
• Ingrezza: Is primarily metabolized by CYP3A4. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase valbenazine exposure, necessitating a dose reduction. Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease exposure, potentially reducing efficacy. Concurrent use with MAOIs is not recommended.

A thorough review of all concomitant medications is essential before initiating either Austedo or Ingrezza to prevent potential drug interactions and adverse effects.

Cost and Accessibility

Both Austedo and Ingrezza are specialty medications and can be very expensive. The cost can be a significant barrier for patients, and insurance coverage varies widely. Patient assistance programs from the manufacturers or other organizations may be available to help reduce out-of-pocket expenses. Discussions with healthcare providers and insurance companies are vital to understand coverage and financial implications.

When to See a Doctor

It is crucial to consult a healthcare professional if you or a loved one experience any of the following:

• New or Worsening Involuntary Movements: If you notice new, uncontrolled, repetitive movements, especially of the face, mouth, tongue, or limbs, particularly if you are taking or have previously taken antipsychotic medications or metoclopramide.
• Symptoms of Huntington's Disease: If you have a family history of HD and begin to experience motor symptoms (chorea, balance issues), cognitive changes (memory problems, difficulty with planning), or psychiatric symptoms (depression, irritability, anxiety).
• Concerns about Current Medications: If you are already on medication for TD or HD and are experiencing side effects, or if the medication does not seem to be effectively controlling your symptoms.
• Mood Changes or Suicidal Thoughts: Especially for individuals with Huntington's disease or those taking Austedo, any new or worsening depression, agitation, anxiety, or thoughts of self-harm warrant immediate medical attention.
• Signs of Serious Side Effects: Such as signs of Neuroleptic Malignant Syndrome (high fever, rigid muscles, confusion), severe dizziness, fainting, or irregular heartbeats.

A neurologist or psychiatrist specializing in movement disorders is typically the most appropriate specialist to diagnose and manage these conditions.

Prevention Strategies

While not all movement disorders are preventable, certain strategies can mitigate the risk or impact of TD and HD.

Preventing Tardive Dyskinesia

• Careful Prescribing of Dopamine Receptor Blockers: Healthcare providers should use the lowest effective dose of antipsychotics or anti-emetics and review the necessity of these medications regularly.
• Using Atypical Antipsychotics: When possible, atypical (second-generation) antipsychotics are generally preferred over typical (first-generation) antipsychotics due to their lower risk of TD, though the risk is not zero.
• Monitoring: Regular monitoring for early signs of TD using tools like the AIMS scale is crucial, especially for patients on long-term dopamine receptor blocking agents.
• Early Intervention: If TD symptoms emerge, reducing the dose of the causative agent, switching to an atypical antipsychotic, or initiating VMAT2 inhibitor treatment promptly may help prevent progression.

Preventing Huntington's Disease

As HD is a genetic disorder, prevention in the traditional sense is not possible for those who inherit the gene. However, genetic counseling plays a vital role:

• Genetic Counseling: For individuals with a family history of HD, genetic counseling can help them understand their risk, the implications of genetic testing, and reproductive options (e.g., preimplantation genetic diagnosis to prevent transmission to offspring).
• Supportive Care: While HD cannot be prevented, early diagnosis and comprehensive supportive care can help manage symptoms and improve quality of life.

Treatment Options Beyond VMAT2 Inhibitors

While Austedo and Ingrezza are leading treatments for TD and HD chorea, it's important to acknowledge that a holistic approach often involves other therapies and supportive care:

• Symptomatic Management: For TD, anticholinergic medications were historically used but are generally not recommended as they can worsen TD. Benzodiazepines may offer some short-term relief for severe agitation but are not a primary treatment.
• Deep Brain Stimulation (DBS): In very select, severe cases of refractory TD or dystonia associated with HD, DBS may be considered, though it is not a standard treatment for chorea.
• Physical, Occupational, and Speech Therapy: These therapies are crucial for managing the motor and swallowing difficulties associated with HD, helping patients maintain function and independence for as long as possible.
• Psychiatric and Psychological Support: Given the high rates of depression, anxiety, and other psychiatric symptoms in HD, mental health support, including antidepressants, mood stabilizers, and psychotherapy, is essential.
• Nutritional Support: Patients with advanced HD often struggle with maintaining weight due to increased caloric expenditure from chorea and difficulty swallowing. Nutritional counseling and interventions are vital.

The treatment plan should always be individualized, considering the patient's specific symptoms, overall health, and personal preferences, often involving a multidisciplinary team of specialists.

Frequently Asked Questions (FAQs)

Are Austedo and Ingrezza interchangeable?

No, Austedo and Ingrezza are not directly interchangeable. While both are VMAT2 inhibitors and treat tardive dyskinesia, Austedo is also approved for chorea associated with Huntington's disease, whereas Ingrezza is not. They also have different dosing schedules (Austedo typically twice daily, Ingrezza once daily) and slightly different side effect and drug interaction profiles. The choice between them depends on the specific diagnosis, patient tolerance, and other individual factors.

Which one is better for tardive dyskinesia?

Both Austedo and Ingrezza have demonstrated significant efficacy in reducing the severity of tardive dyskinesia in clinical trials. There is no definitive "better" medication as individual responses can vary. The choice often comes down to factors like dosing frequency (once-daily Ingrezza vs. twice-daily Austedo), specific side effect concerns, potential drug interactions, and physician preference. A detailed discussion with your healthcare provider is necessary to determine the most suitable option for you.

Can these drugs cure TD or HD?

No, neither Austedo nor Ingrezza are cures for tardive dyskinesia or Huntington's disease. They are symptomatic treatments, meaning they help manage and reduce the severity of the involuntary movements. For TD, they can significantly improve symptoms, but the underlying cause (e.g., prior antipsychotic use) remains. For HD, they address the chorea but do not halt the progressive neurodegeneration or other cognitive and psychiatric symptoms of the disease.

What are the most serious side effects to watch out for?

For both medications, serious side effects include QT prolongation (a heart rhythm abnormality), Parkinsonism (worsening or development of Parkinson-like symptoms), and Neuroleptic Malignant Syndrome (NMS), a rare but life-threatening reaction. Austedo specifically carries a Boxed Warning for depression and suicidality in patients with Huntington's disease, requiring close monitoring for mood changes. Always report any severe or concerning symptoms to your doctor immediately.

How long does it take for them to work?

Patients may start to notice improvements in their involuntary movements within a few weeks of starting treatment with either Austedo or Ingrezza. However, the full therapeutic effect often takes longer, as both medications are typically titrated slowly over several weeks to reach an optimal dose. Consistent adherence to the prescribed dosing regimen is important to achieve the best results.

Conclusion

Austedo and Ingrezza represent crucial therapeutic advancements in the management of complex movement disorders. As VMAT2 inhibitors, they both effectively reduce the involuntary movements characteristic of tardive dyskinesia. However, their distinct indications – with Austedo also offering an FDA-approved option for chorea in Huntington's disease – along with differences in dosing frequency, specific side effect profiles, and drug interaction potential, necessitate a personalized approach to treatment selection.

The decision between Austedo and Ingrezza, or indeed any treatment for these conditions, should always be made in close consultation with a healthcare professional specializing in movement disorders. This allows for a thorough assessment of the patient's specific diagnosis, symptom severity, medical history, concomitant medications, and individual preferences. Understanding these medications empowers patients and caregivers to engage actively in their treatment journey, striving for improved motor control and a better quality of life.

Sources / Medical References

The information provided in this article is for educational purposes only and is not intended as medical advice. It is based on publicly available medical literature, drug prescribing information from the U.S. Food and Drug Administration (FDA), and general medical consensus regarding tardive dyskinesia and Huntington's disease. For specific medical advice, diagnosis, or treatment, always consult with a qualified healthcare professional. Refer to the official prescribing information for Austedo (deutetrabenazine) and Ingrezza (valbenazine) for complete details on indications, dosage, warnings, and side effects.